These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24582273)

  • 1. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
    Ovbiagele B; Goldstein LB; Amarenco P; Messig M; Sillesen H; Callahan A; Hennerici MG; Zivin J; Welch KM;
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):778-84. PubMed ID: 24582273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Goldstein LB; Amarenco P; Szarek M; Callahan A; Hennerici M; Sillesen H; Zivin JA; Welch KM;
    Neurology; 2008 Jun; 70(24 Pt 2):2364-70. PubMed ID: 18077795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Amarenco P; Benavente O; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; Gilbert S; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2009 Apr; 40(4):1405-9. PubMed ID: 19228842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Szarek M; Sillesen H; Rudolph AE; Callahan A; Hennerici M; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2007 Dec; 38(12):3198-204. PubMed ID: 17962589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of early stroke recurrence in transient ischemic attack patients from the PROMAPA study: a comparison of prognostic risk scores.
    Purroy F; Jiménez Caballero PE; Gorospe A; Torres MJ; Alvarez-Sabin J; Santamarina E; Martínez-Sánchez P; Cánovas D; Freijo MM; Egido JA; Girón JM; Ramírez-Moreno JM; Alonso A; Rodríguez-Campello A; Casado I; Delgado-Medeiros R; Martí-Fàbregas J; Fuentes B; Silva Y; Quesada H; Cardona P; Morales A; de la Ossa N; García-Pastor A; Arenillas JF; Segura T; Jiménez C; Masjuán J;
    Cerebrovasc Dis; 2012; 33(2):182-9. PubMed ID: 22237056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of vascular events after nondisabling small and large vessel cerebral ischemia.
    Achterberg S; Pruissen DM; Kappelle LJ; Algra A;
    Cerebrovasc Dis; 2013; 36(3):190-5. PubMed ID: 24135529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
    Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Framingham Coronary Heart Disease Risk Score for predicting cardiac risk after stroke.
    Towfighi A; Markovic D; Ovbiagele B
    Stroke; 2012 Nov; 43(11):2942-7. PubMed ID: 22949478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
    Arsenault BJ; Boekholdt SM; Mora S; DeMicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD
    Am J Cardiol; 2014 Apr; 113(8):1378-82. PubMed ID: 24582532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.